Karthikesalingam A, Holt PJ, Hinchliffe RJ, et al. The diagnosis and management of aortic dissection. Vasc Endovascular Surg. 2010;44(3):165–9.
Flachskampf FA, Daniel WG. Aortic dissection. Cardiol Clin. 2000;18(4):807–17.
Akutsu K. Etiology of aortic dissection. Gen Thorac Cardiovasc Surg. 2019;67(3):271–6.
Khan IA, Nair CK. Clinical, diagnostic, and management perspectives of aortic dissection. Chest. 2002;122(1):311–28.
Mukherjee D, Eagle KA. Aortic dissection-an update. Curr Probl Cardiol. 2005;30(6):287–325.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
Ying SY, Chang DC, Miller JD, et al. The microRNA: overview of the RNA gene that modulates gene functions. Methods Mol Biol. 2006;342:1–18.
Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–7.
Yu T, Ma P, Wu D, et al. Functions and mechanisms of microRNA-31 in human cancers. Biomed Pharmacother. 2018;108:1162–9.
Backes C, Meese E, Keller A. Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects. Mol Diagn Ther. 2016;20(6):509–18.
Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65.
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.
Chen Z, Liang H, Chen X, et al. An Ebola virus-encoded microRNA-like fragment serves as a biomarker for early diagnosis of Ebola virus disease. Cell Res. 2016;26(3):380–3.
Fu Z, Wang J, Wang Z, et al. A virus-derived microRNA-like small RNA serves as a serum biomarker to prioritize the COVID-19 patients at high risk of developing severe disease. Cell Discov. 2021;7(1):48.
Söderberg-Nauclér C. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol. 2008;41(3):218–23.
Collins-McMillen D, Buehler J, Peppenelli M, et al. Molecular determinants and the regulation of human cytomegalovirus latency and reactivation. Viruses. 2018;10(8):444.
Manandhar T, Hò GT, Pump WC, et al. Battle between host immune cellular responses and HCMV immune evasion. Int J Mol Sci. 2019;20(15):3626.
Abdalla AE, Mahjoob MO, Abosalif KOA, et al. Human cytomegalovirus-encoded MicroRNAs: A master regulator of latent infection. Infect Genet Evol. 2020;78:104–19.
Zhang L, Yu J, Liu Z. MicroRNAs expressed by human cytomegalovirus. Virol J. 2020;17(1):34. https://doi.org/10.1186/s12985-020-1296-4.
Goldberger T, Mandelboim O. The use of microRNA by human viruses: lessons from NK cells and HCMV infection. Semin Immunopathol. 2014;36(6):659–74.
Li S, Zhu J, Zhang W, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011;36(6):659–74.
Ding M, et al. Distinct expression profile of HCMV encoded miRNAs in plasma from oral lichen planus patients. J Transl Med. 2018;15(1):133.
Li S, Zhu J, Zhang W, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011;124:175–84.
Pan Y, Wang N, Zhou Z, et al. Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNalpha treatment in chronic hepatitis B patients. Sci Rep. 2016;6:23007.
Barozai N, Barozai MYK, Din M, et al. Differential expressional analysis of serum microRNAs in hepatitis C patients of Quetta, Pakistan. Pure Appl Biol. 2018;7(2):853–62.
Gao Z, Zhou L, Bai J, et al. Assessment of HCMV-encoded microRNAs in plasma as potential biomarkers in pregnant women with adverse pregnancy outcomes. Ann Transl Med. 2021;9(8):638.
Landolfo S, Gariglio M, Gribaudo G, et al. The human cytomegalovirus. Pharmacol Ther. 2003;98(3):269–97.
Goodrum F, Caviness K, Zagallo P. Human cytomegalovirus persistence. Cell Microbiol. 2012;14(5):644–55.
Goodrum F. Human cytomegalovirus latency: approaching the Gordian Knot. Annu Rev Virol. 2016;3(1):333–57.
Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121(5):1673–80.
Goodwin C M, Ciesla J H, Munger J. Who's Driving? Human Cytomegalovirus, Interferon, and NFκB Signaling. Viruses. 2018;10(9):1–18.
Patro ARK. Subversion of immune response by human cytomegalovirus. Front Immunol. 2019;10:1155.
Fannin Rider PJ, Dunn W, Yang E, et al. Human cytomegalovirus microRNAs. Curr Top Microbiol Immunol. 2008;325:21–39.
Liang Q, Wang K, Wang B, et al. HCMV-encoded miR-UL112-3p promotes glioblastoma progression via tumour suppressor candidate 3. Sci Rep. 2017;7:44705.
Deshpande RP, Panigrahi M, Y B V K C, et al. Profiling of microRNAs modulating cytomegalovirus infection in astrocytoma patients. Neurol Sci. 2018; 39(11):1895−1902.
Zhang J, Huang Y, Wang Q, et al. Levels of human cytomegalovirus miR-US25-1-5p and miR-UL112-3p in serum extracellular vesicles from infants with HCMV active infection are significantly correlated with liver damage. Eur J Clin Microbiol Infect Dis. 2020;39(3):471–81.
Pan Y, Wang N, Zhou Z, et al. Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients. Sci Rep. 2016;6:23007.
Romania P, Cifaldi L, Pignoloni B, et al. Identification of a genetic variation in ERAP1 aminopeptidase that prevents human cytomegalovirus miR-UL112-5p-mediated immunoevasion. Cell Rep. 2017;20(4):846–53.
Lisboa LF, Egli A, O’Shea D, et al. Hcmv-miR-UL22A-5p: a biomarker in transplantation with broad impact on host gene expression and potential immunological implications. Am J Transplant. 2015;15(7):1893–902.